Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
Albany New York September 22 2026 Las Vegas Nevada United States As per DelveInsight s assessment globally Multiple Sclerosis pipeline constitutes 75 key companies continuously working towards developing 80 Multiple Sclerosis treatment therapies analysis of Clinical Trials Therapies Mechanism of ... Press release - ABNewswire - Multiple Sclerosis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Biogen, Immune Response BioPharma, Celgene, Novartis, Sanofi, Actelion, Baye - published on openPR.com While there is no cure, a wide range of disease-modifying therapies can help reduce relapse rates, slow disease progression, and improve quality of life. Explore the latest Multiple Sclerosis pipeline insights 2026, including emerging therapies, clinical trials, and market opportunities. * Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. * Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Sclerosis market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. (Albany, New York) - September 22, 2026: The Key Hyperphosphatemia Companies in the market include - Ardelyx, Sanofi, Takeda Pharma, Unicycive Therapeutics, Taisho Pharma, Alebund Pharmaceuticals, FRESENIUS MEDICAL CARE RENAL PHARMACEUTICALS, Astellas pharma, Shield Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Alebund Pharma, Sanofi, Bayer, Keryx Biopharma, Kissei Pharma, Taisho Pharma, Astellas Pharma Inc, Novartis, Sanofi, Mitsubishi Tanabe Pharma, and others. DelveInsight's "Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast-2036 report offers an ... (Albany, New York) -
Original title: “Multiple Sclerosis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Biogen, Immune Response BioPharma, Celgene, Novartis, Sanofi, Actelion, Baye”
foxe1 susceptibility polymorphisms and functional characterization of rare duox2 variants provide new insights into congenital hypothyroidism with thyroid dysgenesis
Original title: “FOXE1 susceptibility polymorphisms and functional characterization of rare DUOX2 variants provide new insights into congenital hypothyroidism with thyroid dysgenesis.”
lrp12 cgg repeat expansions in patients with adult onset non 5q spinal muscular atrophy
Original title: “LRP12 CGG Repeat Expansions in Patients With Adult-Onset Non-5q Spinal Muscular Atrophy.”
pediatric idiopathic multicentric castleman disease is often severe but responsive to siltuximab
Original title: “Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab.”
de novo gain of function variant of dnm1l causes developmental encephalopathy
Original title: “A De Novo Gain-of-Function Variant of DNM1L Causes Developmental Encephalopathy.”
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
Original title: “Government-Owned Inventions; Availability for Licensing”
late onset atrioventricular block and significant conduction disturbances after cardiac interventions in children
Original title: “Late-Onset Atrioventricular Block and Significant Conduction Disturbances After Cardiac Interventions in Children.”
tumor data extraction from unstructured medical reports application of an artificial intelligence enhanced tool in the eastern switzerland cancer registry
Original title: “Tumor data extraction from unstructured medical reports: application of an artificial intelligence-enhanced tool in the Eastern Switzerland Cancer Registry.”
castleman disease unraveling diagnostic challenges through clinical and pathologic perspectives
Original title: “Castleman Disease: Unraveling Diagnostic Challenges Through Clinical and Pathologic Perspectives.”
pulmonary arterial hypertension with signs of venous capillary involvement in connective tissue diseases paradigms and paradoxes
Original title: “Pulmonary arterial hypertension with signs of venous/capillary involvement in connective tissue diseases: paradigms and paradoxes.”